apnea has been researched along with Motor Disorders in 4 studies
Apnea: A transient absence of spontaneous respiration.
Motor Disorders: Motor skills deficits that significantly and persistently interfere with ACTIVITIES OF DAILY LIVING appropriate to chronological age. (from DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 9.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 9.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 5.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 5.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marques, KA | 1 |
| Bruschettini, M | 1 |
| Roehr, CC | 1 |
| Davis, PG | 2 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Schmidt, B | 1 |
| Roberts, RS | 1 |
| Anderson, PJ | 1 |
| Asztalos, EV | 1 |
| Costantini, L | 1 |
| Dewey, D | 1 |
| D'Ilario, J | 1 |
| Doyle, LW | 1 |
| Grunau, RE | 1 |
| Moddemann, D | 1 |
| Nelson, H | 1 |
| Ohlsson, A | 1 |
| Solimano, A | 1 |
| Tin, W | 1 |
| Khurana, S | 1 |
| Shivakumar, M | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Jayashree, P | 1 |
| Ramesh Bhat, Y | 1 |
| Lewis, LES | 1 |
| Dobson, NR | 1 |
| Hunt, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for apnea and Motor Disorders
| Article | Year |
|---|---|
Methylxanthine for the prevention and treatment of apnea in preterm infants.
Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur | 2023 |
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
2 trials available for apnea and Motor Disorders
| Article | Year |
|---|---|
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |